Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52‐week randomized controlled clinical trial

GLP-1 analogue Adult Glycated Hemoglobin Blood Glucose liraglutide clinical trial Liraglutide Overweight Incretins 3. Good health Prediabetic State Diabetes, Gestational Glucose Treatment Outcome Diabetes Mellitus, Type 2 Double-Blind Method Pregnancy Humans Hypoglycemic Agents incretin therapy Female Obesity GLP-1
DOI: 10.1111/dom.15306 Publication Date: 2023-10-17T08:37:20Z
ABSTRACT
We investigated the effect of 52-week treatment with liraglutide, a glucagon-like peptide 1 receptor agonist, on glucose tolerance and incretin in women previous gestational diabetes mellitus (pGDM).Women overweight/obesity pGDM were randomized to once daily subcutaneous liraglutide 1.8 mg or placebo for 52 weeks. Participants underwent oral test (OGTT) isoglycaemic intravenous infusion at baseline weeks, an additional OGTT after drug wash-out.In total, 104 [age: mean ± SD, 38 5 years; fasting plasma (FPG): 5.5 0.4 mmol/L; glycated haemoglobin (HbA1c): 33 4 mmol/mol, bodyweight: 88.2 14.8 kg, body mass index: 31.1 4.3 kg/m2 ] assigned (n = 49) 55). Estimated difference (ETD) area under curve during was -173 (95% confidence interval -250 -97) mmol/L × min, p < .0001, but wash-out disappeared [ETD 58 (-30 146) .536]. Liraglutide reduced FPG -0.2 (-0.4 -0.1) mmol/L, .018], HbA1c [-2.2 (-3.5 -0.8) .018] bodyweight [-3.9 (-6.2 -1.6) .012]. No change observed. The number prediabetes from 64% 10% vs. 50% [adjusted odds ratio 0.10 (0.03-0.32), .002].Treatment weeks improved tolerance, FPG, pGDM. Progression while markedly reduced, 1-week wash-out, lost.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (6)